Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Non-Small Cell Lung Cancer (NSCLC) — Options & Clinical Trial Reference
Molecularly stratified reference covering EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, HER2, NTRK, PD-L1 expression, and recruiting trials.
Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesequivocal_valuesbiomarkers
versionstatuspending_status_valuesequivocal_valuesbiomarkers
Unranked Guideline & FDA-Label Option Categories (92 total)
| Option / Pathway | Category | Primary Sources |
|---|---|---|
| Anatomic resection and nodal assessment | Local treatment | nci_nsclc, calgb140503 |
| Definitive stereotactic radiation review | Local treatment | nci_nsclc, rtog0236 |
| Perioperative pembrolizumab plus platinum chemotherapy | Systemic therapy | peri_pembro, kn671_5y |
| Perioperative nivolumab plus platinum chemotherapy | Systemic therapy | peri_nivo, cm77t, cm77t_ctgov |
| Perioperative durvalumab plus platinum chemotherapy | Systemic therapy | peri_durva, aegean |
| Adjuvant platinum-based chemotherapy | Systemic therapy | nci_nsclc, lace |
| Adjuvant osimertinib | Systemic therapy | tagrisso, adaura, tagrisso_coverage_20261109 |
| Adjuvant alectinib | Systemic therapy | adj_alectinib, alecensa, alina, alecensa_coverage_20261109, alina_ctgov, elevate_2026 |
| Adjuvant pembrolizumab after platinum | Systemic therapy | adj_pembro |
| Adjuvant atezolizumab after platinum | Systemic therapy | adj_atezo |
| Concurrent platinum chemoradiation | Systemic therapy | nci_nsclc |
| Sequential platinum chemoradiation | Systemic therapy | nci_nsclc |
| Durvalumab after concurrent chemoradiation | Systemic therapy | imfinzi, pacific5 |
| Osimertinib after chemoradiation | Systemic therapy | laura, laura_updated_2026 |
| Osimertinib | Systemic therapy | tagrisso, flaura2_os, tagrisso_coverage_20261109 |
View all 92 Non-Small Cell Lung Cancer (NSCLC) reference options →
Recruiting Clinical Trials (46 curated)
| NCT ID | Study Title | Phase |
|---|---|---|
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | PHASE2 |
| NCT03191149 | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | PHASE2 |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | PHASE2/PHASE3 |
| NCT04410796 | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | PHASE2 |
| NCT04486833 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | PHASE1/PHASE2 |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | PHASE2/PHASE3 |
| NCT05099172 | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | PHASE1/PHASE2 |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | PHASE1/PHASE2 |
| NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | PHASE1/PHASE2 |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | PHASE2 |
| NCT05785741 | A Study of DB-1310 in Advanced/Metastatic Solid Tumors | PHASE1/PHASE2 |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | PHASE3 |
View all 46 Non-Small Cell Lung Cancer (NSCLC) clinical trials →